FDA Clears Phase 2 Trial for Neurocrine's Alzheimer's Drug NBI-1117567
NBIX sits 26% above its 52-week low of $122.138.
Summary
The FDA accepted Neurocrine's IND for NBI-1117567, allowing a Phase 2 study in Alzheimer's cognition. This is the third muscarinic agonist from the Nxera collaboration to reach Phase 2, following direclidine (Phase 3) and NBI-1117570 (Phase 2). Nxera receives a $10 million milestone payment, recognized as revenue in Q3 FY2026. The milestone is modest relative to Neurocrine's $15.6B market cap, but the pipeline advancement validates the muscarinic platform and adds a new clinical asset in a high-unmet-need indication. Neurocrine's Q2 beat and raised guidance already reflect strong commercial momentum; this news reinforces the long-term pipeline story.
At the time of this announcement, NBIX was trading at $153.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.6B. The 52-week trading range was $122.14 to $186.12. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.